C-4VXPBetalin Therapeutics
stem cells, tissue engineering, beta cells
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-4VXP
C-4VXPC-4VXPstem cells, tissue engineering, beta cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Betalin Therapeutics stem cells, tissue engineering, beta cells
Betalin is developing an engineered micro-pancreas intended to restore regulated insulin release in diabetic patients. Its approach combines stem cell technology with a tissue-engineered scaffold called the micro-organ matrix, designed to support insulin-producing beta cells. The company’s roadmap describes pre-clinical, Phase I, Phase II, and Phase III development milestones for the micro-pancreas program.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Betalin Therapeutics — Early mechanism · Lower middle. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic